Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
J Gastroenterol
    March 2026
  1. OKADA H, Sugimoto S, Kayashima A, Mikami Y, et al
    Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease.
    J Gastroenterol. 2026 Mar 19. doi: 10.1007/s00535-026-02388.
    >> Share

  2. TSURUOKA N, Takedomi H, Sakata Y, Fujioka S, et al
    Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team.
    J Gastroenterol. 2026 Mar 10. doi: 10.1007/s00535-026-02383.
    >> Share

    February 2026
  3. WANG X, Tu Y, Zhang S, Che T, et al
    Severity of surgical histopathological fibrosis predicted postoperative recurrence in Crohn's disease: a multi-center retrospective cohort study.
    J Gastroenterol. 2026 Feb 26. doi: 10.1007/s00535-026-02374.
    >> Share

  4. OSAKA R, Naito T, Khor SS, Kakuta Y, et al
    HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.
    J Gastroenterol. 2026 Feb 6. doi: 10.1007/s00535-026-02354.
    >> Share

    January 2026
  5. FUJIOKA S, Umeno J, Takeda T, Kinjo K, et al
    Risk of extraintestinal cancer in patients with inflammatory bowel disease: a multicenter retrospective cohort study in Japan.
    J Gastroenterol. 2026 Jan 16. doi: 10.1007/s00535-025-02333.
    >> Share

  6. PU T, Feng R, Wang C, Zhao Y, et al
    METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A modification of SerpinB5 mRNA and FBXO32-dependent NF-kappaB pathway.
    J Gastroenterol. 2026 Jan 4. doi: 10.1007/s00535-025-02341.
    >> Share

  7. NAMBU R, Iwama I, Takeuchi I, Hagiwara SI, et al
    Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study.
    J Gastroenterol. 2026 Jan 3. doi: 10.1007/s00535-025-02334.
    >> Share

  8. FUKUI S, Kishimoto M, Matsuura M, Sakamoto A, et al
    Prevalence, characteristics, and screening of spondyloarthritis in Japanese patients with early inflammatory bowel diseases: a prospective multidisciplinary study.
    J Gastroenterol. 2026;61:46-58.
    >> Share

    November 2025
  9. NISAR M, Awan AR, Ahmad A, Saleem H, et al
    Diagnostic accuracy of anti-integrin alphavbeta6 in ulcerative colitis: a diagnostic meta-analysis.
    J Gastroenterol. 2025 Nov 13. doi: 10.1007/s00535-025-02319.
    >> Share

  10. YOSHIDA A, Takagi T, Kawashima K, Moriya K, et al
    Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study.
    J Gastroenterol. 2025 Nov 7. doi: 10.1007/s00535-025-02313.
    >> Share

  11. MAUDUIT A, Mas E, Sola-Tapias N, Menard S, et al
    Main genetic factors associated with inflammatory bowel diseases and their consequences on intestinal permeability: involvement in gut inflammation.
    J Gastroenterol. 2025;60:1323-1338.
    >> Share

    September 2025
  12. SONG H, Zhou Y, Liu S, Zhang Q, et al
    Long-term risk of inflammatory bowel disease in patients with irritable bowel syndrome: the cross-sectional and longitudinal relationship.
    J Gastroenterol. 2025 Sep 28. doi: 10.1007/s00535-025-02304.
    >> Share

  13. MATSUOKA K, Hirai F, Watanabe K, Hokari R, et al
    Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).
    J Gastroenterol. 2025 Sep 22. doi: 10.1007/s00535-025-02299.
    >> Share

  14. TSUTSUI A, Murakami Y, Nishiwaki Y, Asakura K, et al
    Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn's disease in Japan in 2023.
    J Gastroenterol. 2025 Sep 2. doi: 10.1007/s00535-025-02295.
    >> Share

    July 2025
  15. AKIYAMA S, Ito Y, Shiroyama M, Suzuki S, et al
    Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis: a multicenter I?BRITE cohort study.
    J Gastroenterol. 2025 Jul 8. doi: 10.1007/s00535-025-02279.
    >> Share

  16. ZAKERSKA-BANASZAK O, Ladziak K, Kruszka D, Maciejewski K, et al
    New potential biomarkers of ulcerative colitis and disease course - integrated metagenomic and metabolomic analysis among Polish patients.
    J Gastroenterol. 2025 Jul 4. doi: 10.1007/s00535-025-02280.
    >> Share

  17. KUDO T, Arai K, Iwama I, Hagiwara SI, et al
    Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan.
    J Gastroenterol. 2025 Jul 2. doi: 10.1007/s00535-025-02271.
    >> Share

  18. MORI R, Ogino T, Murakami M, Kayama H, et al
    Group 1 innate lymphoid cells and inflammatory macrophages exacerbate fibrosis in creeping fat through IFN-gamma secretion.
    J Gastroenterol. 2025;60:838-853.
    >> Share

    May 2025
  19. SAWAHASHI M, Kakuta Y, Naito T, Okazaki S, et al
    Autoantibodies against endothelial protein C receptor and integrin alphavbeta6 predict the development of ulcerative colitis.
    J Gastroenterol. 2025 May 15. doi: 10.1007/s00535-025-02263.
    >> Share

  20. JUN YK, Choi Y, Shin CM, Park YS, et al
    Impact of early aggressive treatment on long-term biochemical marker patterns in inflammatory bowel disease.
    J Gastroenterol. 2025 May 2. doi: 10.1007/s00535-025-02244.
    >> Share

    April 2025
  21. MATSUOKA K, Motoya S, Yamamoto T, Matsuura M, et al
    Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data.
    J Gastroenterol. 2025 Apr 21. doi: 10.1007/s00535-025-02249.
    >> Share

  22. UENO N, Sakatani A, Ando K, Saito S, et al
    Educational interventions to enhance support for balancing work and treatment in inflammatory bowel disease patients.
    J Gastroenterol. 2025 Apr 12. doi: 10.1007/s00535-025-02248.
    >> Share

    March 2025
  23. OGINO Y, Sadashima K, Yoshida Y, Takedomi H, et al
    Development of a capsule endoscopy scoring system for the early diagnosis of small bowel Crohn's disease.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02235.
    >> Share

  24. AKIYAMA S, Hayashi R, Takasago T, Kusunoki K, et al
    Prevalence and predictability of the Chicago Classification of Pouchitis in ulcerative colitis: a multicenter study in Japan.
    J Gastroenterol. 2025 Mar 6. doi: 10.1007/s00535-025-02231.
    >> Share

  25. OKABAYASHI S, Itaya T, Yamazaki H, Yanai R, et al
    Estimating cancer risk in immune-mediated inflammatory diseases exposed to varying doses of tumour necrosis factor inhibitors.
    J Gastroenterol. 2025;60:285-293.
    >> Share

    February 2025
  26. KIM MK, Shin SH, Lee CH, Kim S, et al
    Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease.
    J Gastroenterol. 2025 Feb 26. doi: 10.1007/s00535-025-02230.
    >> Share

  27. OKITA M, Takenaka K, Hirai F, Ashizuka S, et al
    Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn's disease activity in the small bowel.
    J Gastroenterol. 2025 Feb 14. doi: 10.1007/s00535-025-02223.
    >> Share

    January 2025
  28. NAGANUMA M, Shiga H, Shimoda M, Matsuura M, et al
    First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.
    J Gastroenterol. 2025 Jan 30. doi: 10.1007/s00535-025-02216.
    >> Share

    December 2024
  29. OKABE M, Yamamoto S, Shiokawa M, Hisamatsu T, et al
    Publisher Correction: Anti-integrin alphavbeta6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
    J Gastroenterol. 2024 Dec 27. doi: 10.1007/s00535-024-02203.
    >> Share

  30. NAGANUMA M
    Reply to "Severe ulcerative colitis: diagnostic criteria and therapy".
    J Gastroenterol. 2024 Dec 14. doi: 10.1007/s00535-024-02200.
    >> Share

  31. NISHIOKA K, Ogino H, Ihara E, Chinen T, et al
    Importance of rectal over colon status in ulcerative colitis remission: the role of microinflammation and mucosal barrier dysfunction in relapse.
    J Gastroenterol. 2024 Dec 13. doi: 10.1007/s00535-024-02199.
    >> Share

  32. CHIBA M
    Severe ulcerative colitis: diagnostic criteria and therapy.
    J Gastroenterol. 2024 Dec 11. doi: 10.1007/s00535-024-02198.
    >> Share

  33. XIONG Z, Li X, Xie M, Guo J, et al
    Small extracellular vesicles derived from adipose mesenchymal stem cells alleviate intestinal fibrosis by inhibiting the FAK/Akt signaling pathway via MFGE8.
    J Gastroenterol. 2024;59:1092-1106.
    >> Share

    November 2024
  34. OKABE M, Yamamoto S, Shiokawa M, Hisamatsu T, et al
    Anti-integrin alphavbeta6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
    J Gastroenterol. 2024 Nov 28. doi: 10.1007/s00535-024-02176.
    >> Share

  35. YASUDA M, Shiokawa M, Kuwada T, Nishikawa Y, et al
    Anti-integrin alphavbeta6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.
    J Gastroenterol. 2024 Nov 16. doi: 10.1007/s00535-024-02169.
    >> Share

  36. KOMATSU H, Morikubo H, Kimura Y, Moue C, et al
    Determination of optimal cutoff value of ulcerative colitis intestinal ultrasound index to estimate endoscopic improvement in ulcerative colitis.
    J Gastroenterol. 2024 Nov 11. doi: 10.1007/s00535-024-02172.
    >> Share

    September 2024
  37. CHEN G, Wu X, Zhu H, Li K, et al
    Multisample lipidomic profiles of irritable bowel syndrome and irritable bowel syndrome-like symptoms in patients with inflammatory bowel disease: new insight into the recognition of the same symptoms in different diseases.
    J Gastroenterol. 2024 Sep 10. doi: 10.1007/s00535-024-02148.
    >> Share

    July 2024
  38. MASSIRONI S, Furfaro F, Bencardino S, Allocca M, et al
    Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials.
    J Gastroenterol. 2024 Jul 9. doi: 10.1007/s00535-024-02130.
    >> Share

    June 2024
  39. TAKAHASHI K, Morita N, Tamano R, Gao P, et al
    Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients.
    J Gastroenterol. 2024 Jun 14. doi: 10.1007/s00535-024-02121.
    >> Share

    May 2024
  40. MATSUOKA K, Yamazaki H, Nagahori M, Kobayashi T, et al
    Correction: Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
    J Gastroenterol. 2024 May 30. doi: 10.1007/s00535-024-02116.
    >> Share

  41. NAGANUMA M
    Reply to "promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy".
    J Gastroenterol. 2024 May 13. doi: 10.1007/s00535-024-02113.
    >> Share

  42. CHIBA M, Kimura K
    Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy.
    J Gastroenterol. 2024 May 4. doi: 10.1007/s00535-024-02111.
    >> Share

  43. IMAZU N, Torisu T, Yokote A, Umeno J, et al
    Arginase 2 attenuates ulcerative colitis by antioxidant effects of spermidine.
    J Gastroenterol. 2024 May 2. doi: 10.1007/s00535-024-02104.
    >> Share

    April 2024
  44. MAKUUCHI M, Kakuta Y, Umeno J, Fujii T, et al
    Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study.
    J Gastroenterol. 2024 Apr 8. doi: 10.1007/s00535-024-02099.
    >> Share

    March 2024
  45. HIRAYAMA D, Hyodo S, Morita K, Nakase H, et al
    Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.
    J Gastroenterol. 2024 Mar 16. doi: 10.1007/s00535-024-02086.
    >> Share

    January 2024
  46. NAGANUMA M, Nakamura N, Kunisaki R, Matsuoka K, et al
    Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.
    J Gastroenterol. 2024 Jan 26. doi: 10.1007/s00535-024-02079.
    >> Share

  47. KOMATSU H, Morikubo H, Kimura Y, Moue C, et al
    A combination of bowel wall thickness and submucosa index is useful for estimating endoscopic improvement in ulcerative colitis: external validation of the Kyorin Ultrasound Criterion.
    J Gastroenterol. 2024 Jan 21. doi: 10.1007/s00535-024-02077.
    >> Share

    November 2023
  48. YOKOTE A, Imazu N, Umeno J, Kawasaki K, et al
    Reply to "Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis".
    J Gastroenterol. 2023 Nov 27. doi: 10.1007/s00535-023-02064.
    >> Share

  49. SUN S, Lv B
    The antiferroptotic effect of indigo on ulcerative colitis.
    J Gastroenterol. 2023 Nov 23. doi: 10.1007/s00535-023-02063.
    >> Share

    October 2023
  50. NAGANUMA M, Kobayashi T, Kunisaki R, Matsuoka K, et al
    Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02048.
    >> Share

    August 2023
  51. WATANABE K, Nojima M, Nakase H, Sato T, et al
    Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.
    J Gastroenterol. 2023 Aug 10. doi: 10.1007/s00535-023-02029.
    >> Share

    July 2023
  52. PARKES G, Ungaro RC, Danese S, Abreu MT, et al
    Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
    J Gastroenterol. 2023 Jul 25. doi: 10.1007/s00535-023-02013.
    >> Share

  53. SAKURAI T, Omori T, Tanaka H, Ito T, et al
    Multicenter prospective registration study of efficacy and safety of capsule endoscopy in Crohn's disease in Japan (SPREAD-J study).
    J Gastroenterol. 2023 Jul 21. doi: 10.1007/s00535-023-02017.
    >> Share

  54. YOKOTE A, Imazu N, Umeno J, Kawasaki K, et al
    Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis.
    J Gastroenterol. 2023 Jul 6. doi: 10.1007/s00535-023-02016.
    >> Share

    June 2023
  55. MATSUOKA K, Yamazaki H, Nagahori M, Kobayashi T, et al
    Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
    J Gastroenterol. 2023 Jun 23. doi: 10.1007/s00535-023-02005.
    >> Share

  56. YOSHIDA H, Shiokawa M, Kuwada T, Muramoto Y, et al
    Anti-integrin alphavbeta6 autoantibodies in patients with primary sclerosing cholangitis.
    J Gastroenterol. 2023 Jun 13. doi: 10.1007/s00535-023-02006.
    >> Share

  57. SHINZAKI S, Sato T, Fukui H
    Antidiabetic drugs for IBD: a long but promising road ahead for drug repositioning to target intestinal inflammation.
    J Gastroenterol. 2023;58:598-599.
    >> Share

    May 2023
  58. MATSUOKA K, Fujii T, Okamoto R, Yamada A, et al
    Correction: Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD).
    J Gastroenterol. 2023 May 5. doi: 10.1007/s00535-023-01998.
    >> Share

    April 2023
  59. WATANABE S, Ogasawara N, Kobayashi S, Kirino S, et al
    Organoids transplantation as a new modality to design epithelial signature to create a membrane-protective sulfomucin-enriched segment.
    J Gastroenterol. 2023;58:379-393.
    >> Share

    March 2023
  60. YAMAKAWA T, Kitamoto H, Nojima M, Kazama T, et al
    Correction: The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection.
    J Gastroenterol. 2023 Mar 8. doi: 10.1007/s00535-023-01979.
    >> Share

  61. NAMBU R, Arai K, Kudo T, Murakoshi T, et al
    Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study.
    J Gastroenterol. 2023 Mar 8. doi: 10.1007/s00535-023-01972.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016